Get App

Co-Partners

Associate Partners

Last Updated : Mar 09, 2015 11:22 AM IST | Source: Moneycontrol.com

Natco Pharma up 4%, launches hepatitis C drug in Nepal

Shares of Natco Pharma gained 4.4 percent intraday on Monday on launching the first generic version of sofosbuvir in Nepal.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Moneycontrol Bureau


Shares of Natco Pharma gained 4.4 percent intraday on Monday on launching the first generic version of sofosbuvir in Nepal.


Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc., under its brand Sovaldi. Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in Nepal.


"Natco markets generic sofosbuvir under its brand HEPCINAT. Natco hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI)," said the company in its filing to the exchange.


Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.


At 10:22 hours IST, the scrip of Natco Pharma was quoting at Rs 1,537, up Rs 23.45, or 1.55 percent on the BSE.

Posted by Sunil Shankar Matkar

First Published on Mar 9, 2015 10:30 am
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant